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Lung Cancer Diagnostic and Treatment Intervals in the
United States
A Health Care Disparity?
Jeffrey T. Yorio, MD,* Yang Xie, PhD,†‡ Jingsheng Yan, PhD,†‡ and David E. Gerber, MD*‡
Introduction: Lung cancer diagnostic and treatment delays have
been described for several patient populations. However, few studies
have analyzed these intervals among patients treated in contempo-
rary health care systems in the United States. We therefore studied
the timing of lung cancer diagnosis and treatment at a U.S. medical
center providing care to a diverse patient population within two
different hospital systems.
Methods: We performed a retrospective analysis of consecutive
patients diagnosed with non-small cell lung cancer stage I to III from
2000 to 2005 at public and private hospitals affiliated with the
University of Texas Southwestern Medical Center. We recorded
patient and disease characteristics; dates of initial radiograph suspi-
cious for lung cancer, diagnosis, and treatment; and overall survival.
Associations between these factors were assessed using univariate
analysis, multivariate logistic regression, and Kaplan-Meier survival
analysis.
Results: A total of 482 patients met criteria for analysis. In univar-
iate analyses, the image-treatment interval was significantly associ-
ated with race, age, income, insurance type, and hospital type (76
days for public versus 45 days for private; p  0.0001). In multi-
variate analysis, only hospital type remained significantly associated
with the image-treatment interval; patients in the private hospital
setting were more likely to receive timely treatment (hazard ratio
1.85; 95% confidence interval, 1.37–2.50; p  0.001). In univariate
analysis, the image-treatment interval was not associated with dis-
ease stage (p  0.27) or with survival (p  0.42).
Conclusion: Intervals between suspicion, diagnosis, and treatment
of lung cancer vary widely among patients. Health care system
factors, such as hospital type, largely account for these discrepan-
cies. In this study, these intervals do not appear to be associated with
clinical outcomes.
Key Words: Non-small cell lung cancer, Disparities, Timing, In-
tervals, Diagnosis.
(J Thorac Oncol. 2009;4: 1322–1330)
Disparities characterize several aspects of lung cancer. Forinstance, clinical stage at presentation, treatment selec-
tion, and overall survival have been associated with patient
race and ethnicity.1–4 For lung cancer and other malignancies,
the degree to which such differences reflect individual versus
institutional factors remains unclear. To address these dispar-
ities, considerable attention has been directed toward the
issue of access to care, including efforts to bring individuals
into the health care system and then optimize their manage-
ment once they are within it.
The nature of these efforts is likely to reflect the clinical
scenario. In some instances, cancer management is a rela-
tively straightforward procedure. For colorectal cancer,
colonoscopy may encompass detection, diagnosis, and pre-
vention in a single setting. In contrast, the evaluation and
treatment of patients with suspected lung cancer is a complex
process. Patients may require percutaneous or bronchoscopic
biopsy, mediastinal lymph node sampling, evaluation for
extrathoracic disease, and assessment of medical fitness for
surgery. Given the challenges of planning and organizing
lung cancer therapy, several studies have evaluated factors
affecting the timing of disease diagnosis and treatment. How-
ever, the overwhelming majority of these studies have been
conducted abroad,5–14 in patient populations and health care
systems distinct from those in the United States. Of the few
U.S.-based studies, a number have been performed within the
Veterans Affairs (VA) Health System,15–17 a single-payer
structure that does not represent the wider American medical
system. The other U.S. studies have focused on specific
demographic subgroups, including Asian immigrants18 and
Native Hawaiians.19
Contemporary health care in the United States is a
complex system encompassing tremendous patient, provider,
payer, and institutional diversity. Therefore, to examine the
predictors and impact of the timing of lung cancer care in this
context, we examined diagnostic and treatment intervals at a
large American medical center providing care to a diverse
patient population within two different hospital systems.
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PATIENTS AND METHODS
Study Setting
Patients treated at three hospitals associated with the
University of Texas (UT) Southwestern Medical Center—
Parkland Health and Hospital System, University Hospital-St.
Paul and University Hospital-Zale Lipshy—and at UT South-
western outpatient clinics were included in this study. Park-
land Health and Hospital System, a 968-bed inpatient hospital
and associated outpatient clinics, is the only public medical
facility in Dallas county. Dallas county is the ninth most
populous county in the United States, with an estimated
2,345,815 people in 2006. It represents a diverse, urban
population with 21.1% blacks, 37.7% Hispanics, and 36.1%
non-Hispanic whites.20 University Hospital—St. Paul is a
271-bed facility and University Hospital—Zale Lipshy is a
144-bed facility. These hospitals serve as the primary private
medical and surgical referral hospitals for UT Southwestern.
Data Extraction
This study was approved by the UT Southwestern
Institutional Review Board. We collected data on patients
with newly diagnosed stage I to III non-small cell lung cancer
(NSCLC) from 2000 to 2005 from the UT Southwestern
(which includes patients seen at UT Southwestern outpatient
clinics, University Hospital—St. Paul and University Hospi-
tal—Zale Lipshy) and the Parkland Health and Hospital
System Tumor Registries (which includes patients seen at
Parkland inpatient and outpatient facilities). These American
College of Surgeons-approved registries identify cancer cases
through review of all surgical pathology reports and hospital
discharge patient lists. We obtained further information, as
needed, from electronic and paper medical records. Year
2000 U.S. Census data was used to obtain median household
income and education levels based on subject residence zip
codes,21 as previously performed.22 If not otherwise avail-
able, subject date of death was obtained from the Social
Security Death Index (http://ssdi.rootsweb.ancestry.com).
We limited our study population to stage I to III and
excluded stage IV disease to focus on subjects treated with
potentially curative intent. Additionally, this represents a
relatively homogeneous patient group, as imaging and diag-
nostic studies are generally focused on thoracic disease. The
time period 2000–2005 was selected because (1) adequate
data were first recorded by the tumor registries in 2000 and
(2) the 2005 cutoff provided sufficient follow-up time for
survival outcomes.
Recording and Definition of Variables
We recorded the following subject data: age at diagno-
sis, gender, race/ethnicity, tumor histology and stage, insur-
ance type, hospital type (public versus private), and residence
zip code. For each zip code, we recorded the median house-
hold income and percentage of adult residents with a high
school degree. Disease stage was based on the most definitive
data available (i.e., surgical staging was used preferentially
over clinical staging). We recorded the dates of the following
events: initial suspicious radiographic study, tissue diagnosis,
initiation of treatment, and death. Initial suspicious imaging
was classified as the first plain radiograph, computed tomog-
raphy (CT), or other imaging study report that documented a
lesion suspicious for malignancy. Date of tissue diagnosis
was defined as the date of final pathology report. In most
patients, tissue was obtained through bronchoscopic or per-
cutaneous needle biopsy. A minority of patients were taken
directly to surgery after the suspicious imaging study and
therefore had the same date of diagnosis and treatment. Date
of treatment was defined as the date of surgery, initial date of
chemotherapy, or initial date of radiation therapy, whichever
occurred first. Invasive staging procedures, such as medias-
tinoscopy or endobronchial ultrasound, were not considered
treatment. Cause of death (cancer related versus other) was
not available.
Statistical Analysis
Descriptive statistics (medians/means for continuous
variables and percentages for discrete variables) were gener-
ated for baseline demographic and clinical characteristics.
Median household income and percentage with high school
diploma were categorized by quartiles based on our popula-
tion of patients. Comparisons of baseline demographic and
clinical characteristics between the two hospital groups (pub-
lic and private) were performed using 2 analysis for cate-
gorical variables and Wilcoxon test for continuous variables.
We used both univariate and multivariate Cox regres-
sion models to explore the association between time intervals
and patient demographic and clinical characteristics. The
intervals included in this analysis were image to diagnosis,
diagnosis to treatment, image to treatment, and diagnosis to
death. Patients who went directly from imaging to surgery
were not included in the image-diagnosis and diagnosis-
treatment intervals but were included in the overall image-
treatment interval. In multivariate data analysis, we included
age, gender, race, hospital type, and insurance type as covari-
ates in the model. The outcome variable for the multivariate
models is time to event, “event” being diagnosis, treatment,
or death depending on the analysis. Therefore, the hazard
ratio (HR), which indicates the likelihood of having an event
at any specific time point, is greater than 1 for shorter
intervals. These models were specified before the analysis to
address potential confounding problems.
A Cox regression model was used to analyze the
association between the image-treatment interval and survival
time. Survival time was defined as the interval between the
date of treatment and the date of death or censoring. The
standard definition of survival time from date of diagnosis to
date of death or censoring was not used to avoid overlap
between survival time (the dependent variable) and the diag-
nosis-treatment interval (the independent variable).
The image-treatment interval was categorized as a con-
tinuous variable, dichotomized by the median interval, ana-
lyzed by 30-day intervals, and dichotomized by formally
recommended image-treatment interval values. Cancer stage
was included as a covariate in the analysis.
All statistical analyses were performed using SAS 9.1
in Microsoft Windows.
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RESULTS
Study Cohort
A total of 482 patients met criteria for analysis. Median
follow-up was 755 days (interquartile range, 269–1458 days).
Coincidentally, 241 patients were treated in the public hos-
pital system, and 241 patients were treated in the private
hospital system. Baseline patient characteristics are listed in
Table 1. Several characteristics differed significantly between
the public hospital and private hospital patient cohorts, in-
cluding age at diagnosis, stage, race, insurance type, house-
hold income, and education levels.
Figure 1 shows the available data for initial suspicious
radiographic study, diagnosis, and treatment time points.
Altogether, we identified the date of initial suspicious radio-
graphic study for 459 patients (95%), date of diagnosis for
362 patients (75%), and date of treatment initiation for 419
patients (87%). A total of 111 patients (23%) went directly
from suspicious radiographic study to treatment (i.e., surgery)
without a preoperative biopsy. These patients were not in-
cluded in the analyses of the image-diagnosis or diagnosis-
treatment intervals but were included in the image-treatment
interval analysis if dates were available. A total of 397
patients were included in the analysis of the image-treatment
interval; 345 patients were included in the image-diagnosis
interval, and 299 patients were included in the analysis of the
diagnosis-treatment interval. Because of the different num-
bers of patients in these groups, median intervals were not
additive. That is, the median image-treatment interval was not
equal to the median image-diagnosis interval plus the median
diagnosis-treatment interval.
TABLE 1. Baseline Patient Characteristics
All Public Hospital Private Hospital Overall p
No. of patients 482 241 241
Individual-level characteristics
Age at diagnosis, mean SD, yr 63.6  11.1 59.2  10.1 68.0  10.2 0.001
Disease stage at diagnosis
Stage I 194 (40.2) 66 (27.4) 128 (53.1) 0.001
Stage II 56 (11.6) 32 (13.2) 24 (10.0)
Stage III 232 (48.1) 143 (59.3) 89 (36.9)
Histology
Adenocarcinoma 234 (48.5) 101 (41.9) 133 (55.2) 0.002
Squamous cell carcinoma 166 (34.4) 86 (35.7) 80 (33.2)
Other 82 (17.0) 54 (22.4) 28 (11.6)
Gender
Male 251 (52.1) 126 (52.3) 125 (51.9) 0.927
Female 231 (47.9) 115 (47.7) 116 (48.1)
Race
Black 142 (29.5) 113 (46.9) 29 (12.0) 0.001
Hispanic 26 (5.4) 20 (8.3) 6 (2.5)
White 296 (61.4) 98 (40.7) 198 (82.2)
Other 18 (3.7) 10 (4.1) 8 (3.3)
Insurance status
Private insurance 132 (27.4) 45 (18.7) 87 (36.1) 0.001
Medicare with supplemental insurance 107 (22.2) 2 (0.8) 105 (43.6)
Medicare without supplemental insurance 97 (20.1) 56 (23.2) 41 (17.0)
Medicaid 21 (4.4) 19 (7.9) 2 (0.8)
County insurance plan 35 (7.3) 35 (14.5) 0 (0.0)
No insurance 66 (13.7) 60 (24.9) 6 (2.4)
Unknown 24 (5.0) 24 (10.0) 0 (0.0)
Resident zip code-level characteristics
Median household income, US Dollars, year 2000
$32,702 131 (27.8) 89 (36.9) 42 (18.3) 0.001
$32,703–39,902 108 (22.9) 58 (24.1) 50 (21.7)
$39,903–51,679 120 (25.5) 64 (26.6) 56 (24.3)
$51,680 112 (23.8) 30 (12.4) 82 (35.7)
Proportion with high school diploma (%)
60.5 123 (26.1) 95 (39.4) 28 (12.2) 0.001
60.6–75.3 117 (24.8) 65 (27.0) 52 (22.6)
75.4–86.5 116 (24.6) 46 (19.1) 70 (30.4)
86.6 115 (24.4) 35 (14.5) 80 (34.8)
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Diagnostic and Treatment Intervals
Tables 2 and 3 show the median diagnostic and treat-
ment intervals according to patient, disease, and health care
system characteristics. Median image-diagnosis intervals are
displayed in Table 2. The median image-diagnosis interval
was 16 days and was significantly associated with hospital
type. The image-diagnosis interval was not significantly as-
sociated with patient age, gender, race, insurance type, in-
come, education, histology, or disease stage. When analyzed
by insurance type, the image-diagnosis interval was shortest
for patients with no health insurance (8 days) and longest for
patients with Medicaid (40 days). In multivariate analysis
(Table 3), both hospital type (HR for private hospital, 1.96;
95% confidence interval CI, 1.40–2.75; p  0.001) and
insurance type (p  0.016) were significantly associated with
the image-diagnosis interval.
Median diagnosis-treatment intervals are also shown in
Table 2. The median overall diagnosis-treatment interval was
33 days. This interval was significantly associated with hos-
pital type and patient age. The diagnosis-treatment interval
varied according to insurance type (median ranging from 28
days for private insurance to 49 days for the county insurance
plan), but these differences were not statistically significant
(p  0.43). Nor was the diagnosis-treatment interval signif-
icantly associated with gender, race, income, education, his-
tology, or disease stage. In multivariate analysis (Table 3),
the diagnosis-treatment interval was associated with hos-
pital type (HR for private hospital, 1.56; 95% CI, 1.10–
2.23, p  0.01).
Median overall image-treatment intervals are shown in
Table 2. The overall median image-treatment interval was 59
days. The image-treatment interval was significantly associ-
ated with race, age, income, insurance type, and hospital type.
The image-treatment interval was not associated with gender,
education level, histology, or disease stage. In multivariate
analysis (Table 3), the image-treatment interval was signifi-
cantly associated with hospital type (HR for private hospital,
1.85; 95% CI, 1.37–2.50, p  0.001).
Association Between Intervals and Outcome
When considered as a continuous variable, the image-
treatment interval was not associated with overall survival
(p  0.93). Figure 2 shows survival curves of patients
stratified according to image-treatment intervals (30 days,
31–60 days, 61–90 days,90 days). There was no difference
overall (p  0.42) or between the shortest and longest
intervals (p  0.45). In a multivariate analysis adjusting for
stage, histology, and age, there was no significant association
between the image-treatment interval and the overall survival
(p  0.19). This association was also evaluated by dichoto-
mizing the population according to formal recommended
intervals of 42 (Swedish Lung Cancer Study Group)7 and 98
(RAND Corporation)23 days. Neither cutoff was significantly
associated with survival (p  0.59 and p  0.47, respec-
tively).
DISCUSSION
To our knowledge, this is the first study to examine the
predictors and impact of lung cancer diagnostic and treatment
intervals in a setting representative of the diversity and
complexities of the contemporary American health care sys-
tem. Our series of 482 patients with stage I to III NSCLC
treated at both public and private hospitals is an optimal
cohort in which to study patient- and system-related factors.
Because the same medical faculty and trainees care for
patients in both the public and the private hospital settings at
UT Southwestern, basic medical practice principles are likely
to be similar. Notably, the patient populations treated in the
two hospital systems differed significantly with respect to
several baseline characteristics. Patients treated in the public
hospital setting were significantly younger, poorer, less edu-
cated, and more likely to come from an underrepresented
minority racial/ethnic group. Public hospital patients were
also more likely to have advanced stage disease (59% stage
III, compared with 37% stage III in the private hospital; p 
0.001). This finding, which has obvious implications on
disease-related outcomes, is consistent with observations for
a number of other cancer types, including breast and head and
neck cancers.22,24
Although a single medical faculty provided care to the
patients in this cohort, we observed several statistically and
clinically significant differences in diagnostic and treatment
intervals. The image-diagnosis interval—which encompasses
Total Patients
482
Image Date
459 patients
No Image Date
23 patients
Diagnosis Date
345 patients
No Diagnosis Date
114 patients
Diagnosis Date
17 patients
No Diagnosis Date
6 patients
Treatment
Date 
285 patients
No Treatment
Date
60 patients
Treatment
Date 
112 patients
Treatment
Date 
16 patients
Treatment
Date 
6 patients
No Treatment
Date
2 patients
No Treatment
Date
1 patient
No Treatment
Date
0 patients
FIGURE 1. Flow of patients
through data collection points. Im-
age-diagnosis analysis: 345 pa-
tients. Diagnosis-treatment analysis:
301 patients. Image-treatment
analysis: 397 patients. Denotes
inclusion in interval analysis.
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radiographic interpretation, a confirmatory imaging study (in
some cases), scheduling and performing a biopsy, and pa-
thology interpretation—was significantly associated with
hospital type and insurance type. The range among various
insurance types was particularly broad. The shortest interval
(8 days) occurred among individuals with no health insur-
ance. This unexpected finding may reflect the practice of
completing a full diagnostic evaluation while these patients
remain hospitalized, for fear that it will not occur after
discharge. The longest interval (40 days) occurred among
individuals with Medicaid. Whether this delay is related to
preapproval requirements for procedures is not clear.
The diagnosis-treatment interval—which often in-
cludes further imaging studies to evaluate for extrathoracic
disease (e.g., positron emission tomography scan and brain
magnetic resonance imaging), mediastinal staging (e.g., me-
TABLE 2. Association Between Patient Characteristics and Intervals
Image-Diagnosis
Interval (d)
Diagnosis-Treatment
Interval (d)
Image-Treatment
Interval (d)
Median
(25–75% IQR) Overall p
Median
(25–75% IQR) Overall p
Median
(25–75% IQR) Overall p
All patients 16 (6–43) 33 (20–53) 59 (34–93)
Gender
Female 19 (8–48) 0.10 35 (20–56) 0.18 64 (36–98) 0.37
Male 15 (5–40) 32 (18–50) 52 (33–90)
Race/ethnicity
White 17 (8–38) 0.86 30 (17–50) 0.35 54 (31–89) 0.04
Black 15 (5–61) 38 (21–58) 71 (37–116)
Hispanic 9 (4–59) 43 (30–71) 70 (45–136)
Other 17 (3–29 35 (25–50) 48 (20–72)
Age (yr)
65 15 (6–42) 0.84 38 (24–56) 0.04 63 (36–99) 0.02
65 18 (6–44) 29 (16–47) 55 (29–90)
Income quartile
1st ($32,702) 19 (4–50) 0.27 36 (21–56) 0.27 65 (39–110) 0.02
2nd ($32,703–39,902) 14 (7–39) 35 (15–62) 59 (33–99)
3rd ($39,903–51,679) 18 (6–46) 32 (20–49) 66 (37–92)
4th ($51,680) 16 (8–30) 29 (17–55) 45 (29–77)
Education quartilea
1st (60.5%) 21 (5–61) 0.63 34 (20–56) 0.68 65 (39–115) 0.17
2nd (60.6–75.3%) 13 (5–33) 38 (20–54) 60 (39–92)
3rd (75.4–86.5%) 16 (6–39) 32 (15–53) 55 (29–96)
4th (86.6%) 17 (8–37) 30 (20–52) 50 (30–84)
Histology
Adenocarcinoma 20 (8–46) 0.39 32 (18–54) 0.53 58 (34–93) 0.9
Squamous cell 14 (6–43) 33 (22–52) 61 (35–92)
Otherb 15 (6–34) 34 (16–54) 62 (34–103)
Stage
I 19 (12–43) 0.26 33 (18–54) 0.12 59 (34–105) 0.27
II 16 (7–46) 38 (26–56) 65 (39–101)
III 14 (4–41) 32 (17–52) 58 (32–89)
Insurance type
Private 16 (7–44) 0.33 28 (16–46) 0.43 51 (31–90) 0.003
Medicare with supplemental insurance 20 (10–39) 31 (17–54) 49 (29–82)
Medicare without supplemental insurance 18 (6–52) 30 (10–50) 62 (30–106)
Medicaid 40 (9–98) 43 (26–68) 140 (48–187)
County insurance plan 25 (11–38) 49 (32–65) 76 (45–101)
No insurance 8 (3–26) 42 (31–56) 65 (39–98)
Hospital type
Public 17 (6–52) 0.02 40 (26–58) 0.002 76 (44–116) 0.001
Private 15 (6–33) 27 (15–46) 45 (26–78)
a Percentage of area residents with high school diploma.
b Includes large cell, adenosquamous, and unspecified.
IQR, interquartile range.
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diastinoscopy or endobronchial ultrasound), assessment of
medical fitness for therapy (e.g., pulmonary function tests),
and selection, scheduling, and initiation of definitive treat-
ment—was significantly associated with patient age and hos-
pital type in univariate analysis and with hospital type in
multivariate analysis.
The overall image-treatment interval, which encom-
passes the evaluations and planning required for the image-
diagnosis and diagnosis-treatment intervals, was 59 days. It
was associated with patient race, income, and age; hospital
type; and insurance type in univariate analysis. The interval
was 31 days longer in the public hospital (76 days) than in the
private hospital setting (45 days). Again, the range according
to insurance type was pronounced, from approximately 50
days for patients with private insurance to 140 days for
patients with Medicaid (p  0.001). That hospital type was
the only variable significantly associated with the overall
image-treatment interval in multivariate analysis may suggest
that health care system factors, rather than patient factors, are
the primary determinants of lung cancer diagnosis and treat-
ment timing in the United States. These observations are
consistent with those reported for other disease types. In a
series of patients with breast cancer, those treated at a public
hospital had a median evaluation-to-treatment interval of 43
days compared with only 24 days for patients treated in a
private practice setting (p 0.001).25 The precise reasons for
these disparities are not known. Potential institutional factors
include, among others, availability of resources (e.g., CT
scanners, interventional radiologists, operating room or radi-
ation therapy suite time), coordination of care, and payer
administrative requirements.
How does the overall image-treatment interval in this
study compare with those in earlier reports? In a recent
Finnish study, the median interval from referral by a primary
care physician to pathologic diagnosis was 23 days, and the
median interval from diagnosis to treatment was 15 days.5
TABLE 3. Association Between Patients Characteristics and Intervals—Multivariate Analysis
Image-Diagnosis Interval (d) Diagnosis-Treatment Interval (d) Image-Treatment Interval (d)
Hazard Ratio (95% CI) Overall p Hazard Ratio (95% CI) Overall p Hazard Ratio (95% CI) Overall p
Age
65 yr 1 (Reference) 0.79 1 (Reference) 0.24 1 (Reference) 0.64
65 yr 1.05 (0.76–1.44) 1.24 (0.87–1.79) 1.08 (0.79–1.48)
Gender
Male 1 (Reference) 0.37 1 (Reference) 0.12 1 (Reference) 0.75
Female 0.90 (0.71–1.14) 0.83 (0.65–1.05) 0.97 (0.79–1.19)
Race
White 1 (Reference) 0.40 1 (Reference) 0.74 1 (Reference) 0.61
Black 1.24 (0.94–1.64) 0.96 (0.70–1.32) 1.04 (0.80–1.36)
Hispanic 0.91 (0.56–1.51) 0.75 (0.45–1.25) 0.77 (0.48–1.24)
Other 1.17 (0.65–2.13) 0.93 (0.48–1.80) 1.19 (0.63–2.24)
Hospital
Public 1 (Reference) 0.001 1 (Reference) 0.014 1 (Reference) 0.001
Private 1.96 (1.40–2.75) 1.56 (1.10–2.23) 1.85 (1.37–2.50)
Insurance status
Private insurance 1 (Reference) 0.016 1 (Reference) 0.39 1 (Reference) 0.33
Medicare with supplemental
insurance
0.75 (0.50–1.11) 0.63 (0.41–0.95) 0.80 (0.56–1.15)
Medicare without supplemental
insurance
0.98 (0.68–1.41) 0.86 (0.56–1.31) 0.84 (0.59–1.20)
Medicaid 0.87 (0.49–1.53) 0.92 (0.51–1.68) 0.56 (0.32–1.01)
County insurance plan 1.39 (0.86–2.25) 0.94 (0.55–1.60) 0.99 (0.63–1.57
No insurance 1.84 (1.23–2.75) 0.96 (0.64–1.44) 1.08 (0.73–1.58)
Hazard ratio 1, shorter interval.
FIGURE 2. Association between image-treatment intervals
and survival.
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This translates into approximately a 38-day interval between
imaging and treatment, assuming referral to a specialist
occurred in response to a suspicious radiographic study.
Unlike the present cohort, this series included patients with
small cell lung cancer, a biologically aggressive histology
that is typically evaluated and treated in an expedited manner.
A Swedish series, which included all stages of NSCLC,
demonstrated a median interval of 45 days from evaluation by
a chest physician, to treatment initiation.7 In a series of stage
I to II NSCLC cases at the San Francisco VA Hospital, a
median interval of 82 days from detection of a pulmonary
lesion to surgical intervention was reported.26
A number of professional organizations have put forth
specific recommendations regarding the optimal timing of
lung cancer diagnosis and treatment. The Swedish Lung
Cancer Study Group recommends that treatment should be
initiated within 42 days of suspicious imaging.7 The British
Thoracic Society recommends that no more than 70 days
elapse between radiograph and thoracotomy.27 The RAND
Corporation recommends that treatment be initiated within 42
days of diagnosis and that total time from initial abnormal
radiograph to treatment not exceed 98 days.23 Whether pa-
tients in our cohort achieved these recommendations was
highly dependent on hospital type. Overall, 37% of patients
had an image-treatment interval of 42 days or less: 47% of
patients in the private hospital setting met this cutoff, com-
pared with 24% of patients in the public hospital setting (p 
0.001). Overall, 76% of patients had an image-treatment
interval of 98 days or less: 85% in the private hospital setting
met this cutoff, compared with 66% of patients in the public
hospital setting (p  0.001).
Despite formal recommendations, the impact of diag-
nostic and treatment delays on the outcomes of patients with
NSCLC remains unclear.28 In the present series, we found no
association between the image-treatment interval and overall
survival, an observation consistent with the majority of ear-
lier studies.5,12,26,29,30 Although a small number of studies
have reported worse survival in patients experiencing delays
in diagnosis and treatment,31–33 two series have described the
inverse association, with worse outcomes among patients
with shorter intervals.7,10 In contrast to our present report,
intervals in these two studies included the time from symp-
tom onset. A shorter overall interval may have therefore
reflected more rapid disease progression and greater clinical
urgency. Similar observations have been made for other
cancer conditions, such as metastatic epidural spinal cord
compression. In the cord compression literature, a shorter
interval between the onset of motor symptoms and hospital
presentation has paradoxically been associated with worse
ambulatory outcomes, presumably because of greater bio-
logic aggressiveness.34–36
The estimated tumor volume doubling time of NSCLC
cancer ranges 2 to 6 months and is generally longer for
adenocarcinoma histology than for squamous cell tumors.37,38
In a British study of 29 patients with lung cancer awaiting
radical (potentially curative) radiation therapy, the delay
between diagnostic and planning CT scans ranged 18 to 131
days (median 54 days).11 During this time period, there was
a median increase in tumor size of 19% (range, 0–373%).
Four patients had tumor enlargement precluding the initially
planned therapy, and two patients had symptom progression
rendering them unfit for radical treatment. In this study, the
median image-treatment interval was comparable, at 58 days.
Although we did not record tumor sizes, we did evaluate
disease stage and found no association with the image-
treatment interval. Similarly, the majority of earlier studies
have found no association between treatment delays and
disease stage.6,9,10,30
Although the association between the timing of lung
cancer care and conventional clinical endpoints, such as
disease stage and survival, remains uncertain, prolonged
intervals between suspicion, diagnosis, and treatment may
impact other performance markers, such as patient emotional
well being, quality of life, and cost of care. Accordingly, a
number of interventions to provide timely and efficient care
have been reported. These have included multidisciplinary
thoracic conferences and clinics, patient care coordinators,
referral guidelines, and clear, culturally appropriate patient
information.17,39–42 The degree to which these approaches are
applicable in the current U.S. health care system is not clear.
Unlike single-payer structures in other countries or in the VA
system, administrative requirements for individual patients in
the United States may vary widely, even within a single
health care institution. For instance, in this study, patients
with Medicaid had an overall treatment delay more than twice
as long as patients with private insurance or other govern-
ment-provided benefits (Medicare, county health plan). Even
when controlling for hospital type, the difference in overall
image-treatment intervals between Medicaid and private in-
surance remained significant (p  0.05). Thus, in the United
States, efforts to expedite the diagnosis and treatment of lung
cancer might benefit from incorporating extrainstitutional
factors into their design.
This study has a number of limitations. Because of a
relatively small sample size, the study may be underpowered
to detect smaller differences in clinical outcomes associated
with diagnostic and treatment intervals. Although the study
cohort encompasses a racially and socioeconomically diverse
patient population, the degree to which these findings are
generalizable to other institutions and other regions of the
country are uncertain. The exclusion of patients with stage IV
NSCLC—whose symptoms, evaluation, and treatment often
differ markedly from patients with stage I to III disease—
could, in theory, systematically exclude patients with long
delays resulting in progression to advanced disease, thereby
obscuring associations between timeliness, stage, and out-
comes. It is also unclear to what extent patients received
some of their care outside of the UT Southwestern system and
whether this was associated with intervals or outcomes. In
addition, we chose to measure overall survival from the date
of treatment, rather than the more commonly used date of
diagnosis, to avoid overlap between the variables under
study. This definition may shorten the apparent survival time
for patients with long diagnosis-treatment intervals and po-
tentially bias the results. However, the median diagnosis-
treatment interval (33 days) is far shorter than the median
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overall survival (854 days) in the study cohort, so this effect
would be small. Finally, because individuals with more
symptomatic disease may undergo more timely evaluation
and treatment, there may be residual confounding of the
relationship between intervals and clinical outcomes.
In conclusion, this study demonstrates that, in a con-
temporary U.S. health care system, intervals between suspi-
cion, diagnosis, and treatment of lung cancer vary widely and
are predominantly associated with system variables such as
insurance and hospital type. These intervals were not associ-
ated with disease stage or overall survival. However, their
impact on quality of life and cost of care remains unknown.
In the future, if CT-based lung cancer screening is proven to
decrease mortality and is instituted in the United States, the
number of individuals requiring further evaluation of sus-
pected lung cancers may expand substantially. Even in the
absence of such programs, it is already apparent that chest CT
scans are being used increasingly in routine clinical care—for
the evaluation of suspected venous thromboembolic disease,
coronary artery disease, atypical infections, and the like.
Consequently, the number of patients with radiographic stud-
ies suspicious for lung cancer is expected to grow. An
organized and timely approach to subsequent diagnostic and
therapeutic measures may benefit these individuals and re-
duce this health care disparity.
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